Pay in 4 interest-free payments of $6.29 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Disclosures Shinya Furukawa has received lecture fees from Novo Nordisk Pharma Ltd., Boehringer Ingelheim Pharmaceuticals, Inc., Sumitomo Dainippon Pharma Co., Ltd., Ono Pharmaceutical Co., LTD., Eli Lilly and Company, and Sanofi
Patients with severe gastrointestinal disease, including severe gastroparesis, should discuss risks with their healthcare provider before starting treatment
available in chewable tablets and capsules
Using the latest drugs to support people to lose weight will be a game-changer by helping to tackle dangerous obesity-related health conditions such as high blood pressure, diabetes and cancer, he said, adding that Wegovy and similar drugs could reduce pressure on hospitals, help people live longer and healthier lives, and help cut waiting lists for healthcare
The post says GLP-1 therapy may not produce significant weight loss in non-overweight patients, but that improved glucose control, cardiovascular protection, and reduced inflammation remain clinically meaningful
